The digital therapeutics company Devicare, a CataloniaBio & HealthTech member, and the multinational company Exeltis have signed an agreement to market the Lit-Control® family of products in Spain.
Lit-Control® is the world's first digital therapeutics solution that allows the most common urological diseases to be prevented and treated effectively from home while also improving patients' adherence to the treatment.
“We're excited to work with Exeltis to expand the use of Lit-Control® and provide a response to the uncovered medical needs in the area of urology thanks to the constant work with the scientific-medical community and patients” says Rosendo Garganta, CEO of Devicare.
Lit-Control® has demonstrated its accuracy, safety and efficacy in clinical studies.
Comments